Girard Partners’s Sarepta Therapeutics SRPT Stock Holding History

Girard Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-470	Closed	-$75K	–	740
2018 Q3	$75K	Buy	+470	New	+$64.3K	0.01%	390

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Girard Partners's SRPT Position: Q4 2018 in Review

Girard Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 470 shares — an estimated $75K sold.

Girard Partners first reported a position in SRPT in Q3 2018 and held it in 1 quarter. The position peaked at $75K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Girard Partners reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 470 Sarepta Therapeutics shares in Q4 2018, an estimated $75K.
Girard Partners first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 1 quarter.
Girard Partners's Sarepta Therapeutics position peaked at $75K in Q3 2018.
336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.